



Clinical trial results:

A multicenter, randomized, parallel, double-blind, clinical trial study to assess the efficacy and safety of Fluocinolone Acetonide 0.025% Otic Solution compared to Placebo in patients with otic eczema.

Summary

EudraCT number	2011-004172-11
Trial protocol	ES
Global end of trial date	22 March 2013

Results information

Result version number	v1 (current)
This version publication date	16 February 2016
First version publication date	09 July 2015
Summary attachment (see zip file)	FLUOTIII/11ES01 Synopsis CSR (FLUOTIII_11ES01 Synopsis CSR Final 25June2013.pdf)

Trial information

Trial identification

Sponsor protocol code	FLUOTIII/11ES01
-----------------------	-----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01996748
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Laboratorios SALVAT, S.A.
Sponsor organisation address	Gall, 30-36, Esplugues de Llobregat, Spain, 08950
Public contact	Medical Department, Laboratorios SALVAT, S.A., +34 933946469, clinicaltrials@salvatbiotech.com
Scientific contact	Medical Department, Laboratorios SALVAT, S.A., +34 933946470, ejimenezv@salvatbiotech.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 March 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 March 2013
Global end of trial reached?	Yes
Global end of trial date	22 March 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of Fluocinolone Acetonide 0.025% otic solution compared to placebo for the reduction of itching after 8 days of starting treatment in patients with otic eczema.

Protection of trial subjects:

Not applicable

Background therapy:

Not applicable

Evidence for comparator:

The availability of medical treatment is very diverse depending on the EU country; there is not a "gold standard" for this condition. In the absence of a general well established treatment and based on the NOTE FOR GUIDANCE ON CHOICE OF CONTROL GROUP IN CLINICAL TRIALS (CPMP/ICH/364/96), a placebo controlled trial was considered the best design option.

Actual start date of recruitment	09 March 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 135
Worldwide total number of subjects	135
EEA total number of subjects	135

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	109
From 65 to 84 years	26

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

The recruitment period was from 9th March 2012 to 22nd March 2013.

Pre-assignment

Screening details:

Male and female patients aged 12 years or older with clinical diagnosis of otic eczema suitable for local treatment according to the investigator.

Patients must have moderate or severe itching in the ear canal (with or without involvement of the pinna), and otoscopic image of scaling in the ear canal skin.

Period 1

Period 1 title	Study period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

Both Fluocinolone Acetonide 0.025% otic solution and the placebo had identical organoleptical characteristics. The randomization data remained strictly confidential and only authorized persons had access, until the definitive creation of the database.

In case of emergency, for opening the randomization codes, there were a complete set of emergency codes at the investigator's site. The opening of said codes had to be reported to the study monitor immediately and duly recorded.

Arms

Are arms mutually exclusive?	Yes
Arm title	Fluocinolone acetonide
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Fluocinolone acetonide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Ear drops, solution in single-dose container
Routes of administration	Auricular use

Dosage and administration details:

Administer the contents of one 0.40 ml single dose vial twice a day to the affected ear(s) for seven days

Arm title	Placebo
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Ear drops, solution in single-dose container
Routes of administration	Auricular use

Dosage and administration details:

Administer the contents of one 0.40ml single-dose vial twice a day to the affected ear(s) for seven days

Number of subjects in period 1	Fluocinolone acetoneide	Placebo
Started	66	69
Completed	58	63
Not completed	8	6
Physician decision	2	-
Consent withdrawn by subject	-	1
Adverse event, non-fatal	1	4
peronal reasons	1	-
Lost to follow-up	4	1

Baseline characteristics

End points

End points reporting groups

Reporting group title	Fluocinolone acetonide
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Primary: Change in itching on Days 4-8 compared to baseline

End point title	Change in itching on Days 4-8 compared to baseline
End point description:	
End point type	Primary
End point timeframe:	
Day 4-8	

End point values	Fluocinolone acetonide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	68		
Units: scores				
arithmetic mean (inter-quartile range (Q1-Q3))	-1.63 (-2 to -1.1)	-1.25 (-1.75 to -0.84)		

Statistical analyses

Statistical analysis title	ANCOVA on the itching change from baseline
Comparison groups	Fluocinolone acetonide v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.05
Method	ANCOVA

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All study period

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.0
--------------------	------

Reporting groups

Reporting group title	Fluocinolone Acetonide
-----------------------	------------------------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	Fluocinolone Acetonide	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 66 (0.00%)	0 / 69 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Fluocinolone Acetonide	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 66 (7.58%)	9 / 69 (13.04%)	
General disorders and administration site conditions			
Application site pruritus			
subjects affected / exposed	1 / 66 (1.52%)	0 / 69 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	3 / 66 (4.55%)	4 / 69 (5.80%)	
occurrences (all)	4	4	
Ear disorder			
subjects affected / exposed	1 / 66 (1.52%)	0 / 69 (0.00%)	
occurrences (all)	1	0	

Ear pain			
subjects affected / exposed	0 / 66 (0.00%)	1 / 69 (1.45%)	
occurrences (all)	0	1	
Otitis externa			
subjects affected / exposed	0 / 66 (0.00%)	4 / 69 (5.80%)	
occurrences (all)	0	4	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 June 2012	Inclusion of a new centre.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported